We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioScrip's Dull 2017 Earnings a Woe, Core Business Robust
Read MoreHide Full Article
On Mar 14, we issued an updated research report on BioScrip, Inc. . Although the company struggles with reimbursement challenges, its core business continues to grow. The stock has a Zacks Rank #4 (Sell).
BioScrip exited the fourth quarter of 2017 on a dismal note with lower-than-expected earnings performance. Although, revenues were above the consensus mark, the huge year-over-year decline was a disappointment. This downside was due to a shift in the company’s strategy to solely focus on growing core revenue mix including contract changes with United Healthcare, which were completed as of September 30, 2017.
Also, external challenges like reimbursement cuts persisting throughout 2017 pertaining to the 21st century Cures Act hampered growth. Full-year result was thus discouraging as a result of the catastrophic disruption from hurricanes Irma and Harvey in the third quarter besides the Cures Act reimbursement cuts.
In the past three months, shares of BioScrip have underperformed the broader industry. The stock has gained 2.6% compared with the 9.1% rise of the broader industry.
The healthcare industry also wades through a highly competitive scenario. In fact BioScrip’s rivals include large and well-established companies equipped with higher financial, marketing and technological resources.
On a positive note, this Denver, CO-based leading Infusion Service provider has continued to progress with its new multi-faceted CORE plan to improve the financial position. The scheme involves identifying and executing strategies to accelerate core revenue growth, build a favorable product mix, drive operational efficiency, raise revenue collection as well as increase employee effectiveness.
Additionally, in the fourth quarter, the company made a significant advancement by implementing its single repeatable model, which enforces operating cost reduction on the back of solid synergies drawn, supply chain rationalization, growth in nursing productivity, enhanced shipping utilization and improving patient on-boarding times.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and PerkinElmer .
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
BioScrip's Dull 2017 Earnings a Woe, Core Business Robust
On Mar 14, we issued an updated research report on BioScrip, Inc. . Although the company struggles with reimbursement challenges, its core business continues to grow. The stock has a Zacks Rank #4 (Sell).
BioScrip exited the fourth quarter of 2017 on a dismal note with lower-than-expected earnings performance. Although, revenues were above the consensus mark, the huge year-over-year decline was a disappointment. This downside was due to a shift in the company’s strategy to solely focus on growing core revenue mix including contract changes with United Healthcare, which were completed as of September 30, 2017.
Also, external challenges like reimbursement cuts persisting throughout 2017 pertaining to the 21st century Cures Act hampered growth. Full-year result was thus discouraging as a result of the catastrophic disruption from hurricanes Irma and Harvey in the third quarter besides the Cures Act reimbursement cuts.
In the past three months, shares of BioScrip have underperformed the broader industry. The stock has gained 2.6% compared with the 9.1% rise of the broader industry.
The healthcare industry also wades through a highly competitive scenario. In fact BioScrip’s rivals include large and well-established companies equipped with higher financial, marketing and technological resources.
BioScrip, Inc. Price
BioScrip, Inc. Price | BioScrip, Inc. Quote
On a positive note, this Denver, CO-based leading Infusion Service provider has continued to progress with its new multi-faceted CORE plan to improve the financial position. The scheme involves identifying and executing strategies to accelerate core revenue growth, build a favorable product mix, drive operational efficiency, raise revenue collection as well as increase employee effectiveness.
Additionally, in the fourth quarter, the company made a significant advancement by implementing its single repeatable model, which enforces operating cost reduction on the back of solid synergies drawn, supply chain rationalization, growth in nursing productivity, enhanced shipping utilization and improving patient on-boarding times.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and PerkinElmer .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>